title: Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.
authors.affiliation: Centro Universitario Contra el Cáncer, Hospital Universitario Universidad Autónoma de Nuevo León, Monterrey, México.
authors.forename: Alberto
authors.initials: A
authors.lastname: Ocaña
authors.forename: Eitan
authors.initials: E
authors.lastname: Amir
authors.forename: Francisco
authors.initials: F
authors.lastname: Vera
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Eisenhauer
authors.forename: Ian F
authors.initials: IF
authors.lastname: Tannock
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab